演題詳細

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科
 
前へ戻る

Comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

演題番号 : PS-1-65

植村 麻希子 (Makiko Uemura):1、今滝 修 (Osamu Imataki):1、河内 康憲 (Yasunori Kawachi):2,3、福本 哲也 (Tetsuya Fukumoto):3、井出 眞 (Makoto Ide):3、大西 宏明 (Hiroaki Onishi):3、川上 公宏 (Kimihiro Kawakami):4、脇 正人 (Masato Waki):4、星島 康男 (Yasuo Hoshijima):5、松岡 亮仁 (Akihito Matsuoka):6、田岡 輝久 (Teruhisa Taoka):6、黒井 大雅 (Taiga Kuroi):7、岩井 艶子 (Tsuyako Iwai):8、横倉 繁行 (Shigeyuki Yokokura):1、新谷 高理 (Takamichi Shintani):1、脇 房子 (Fusako Waki):1、松本 謙介 (Kensuke Matsumoto):1、松永 卓也 (Takuya Matsunaga):1

1:Division of Hematology, Kagawa University, Kagawa, Japan、2:Department of Internal Medicine, Division of Hematology, Kaisei General Hospital, Kagawa, Japan、3:Department of Internal Medicine, Division of Hematology, Takamatsu Red Cross Hospital, Kagawa, Japan、4:Department of Internal Medicine, Division of Hematology, Kagawa Prefectural Central Hospital, Kagawa, Japan、5:Department of Internal Medicine, Division of Hematology, Takamatsu Municipal Hospital, Kagawa, Japan、6:Department of Internal Medicine, Division of Hematology, Sakaide City Hospital, Kagawa, Japan、7:Department of Internal Medicine, Division of Hematology, KKR Takamatsu Hospital, Kagawa, Japan、8:Department of Pediatrics, Division of pediatric oncology, Kagawa National Children's Hospital, Kagawa, Japan

 

To illustrate an influence of comorbidity at diagnosis for treatment outcome of CML, we evaluated comorbidity index and some prognostic scoring systems under a conduct of a community-wide retrospective study. Methods: Chart abstraction form was used to survey CML diagnosed between November 2001 and December 2012 in Kagawa. We used Charlson Comorbidity Index (CCI) to extract concomitant disease or pathogenic status, and calculated Sokal and Hasford score to compare a predictability of prognosis with CCI. Totally 77 cases were enrolled, 33 were females, and a median age was 56 years old (range 6-89). All but one case, who was in accelerated phase, were in chronic phase at diagnosis. CCI at diagnosis was scored between 2 and 11. Treatment responses were obtained as following; 45 responders > major molecular response (>MMR), 13 complete hematological response (CHR), and 11 complete cytogenetic response (CCyR). Fifty-eight cases (75.3%) achieved CCyR at 12 months after administration of TKIs. As of the median follow-up period was 53.2 months (range 11 days to 133 months), only 4 died due to pneumonia for 3 and unknown cause for 1. Only one case underwent stem cell transplantation because of a concordance with myelodysplastic syndrome and this case was not censored for survival analysis. The risk category (low, intermediate, and high) assessed by Sokal score and Hasford score had good accordance (72.3%), and CCI more than 3 had significantly poor survival from diagnosis (P<0.001). Conclusion: Concomitance of comorbidity is associated with poor treatment outcome with TKIs.

前へ戻る